

CBOE Research Circular #RS14-419

Date: August 5, 2014

To: Permit Holders

From: Scott Speer

RE: Idenix Pharmaceuticals, Inc. ("IDIX"):
Merger Completed -- Cash Settlement

The NASDAQ has informed the CBOE that effective for August 5, 2014, a Merger has been completed between Idenix Pharmaceuticals, Inc. ("IDIX") and Imperial Blue Corporation, a wholly owned subsidiary of Merck & Co., Inc. ("MRK"). According to the terms of the Merger, each outstanding Share of IDIX Common Stock was converted into the right to receive **\$24.50 cash**, without interest, per IDIX share. Please be aware that Idenix Pharmaceuticals, Inc. had been the subject of a tender offer by Imperial Blue Corporation to purchase all outstanding Shares of IDIX Common Stock at \$24.50 per IDIX Share, net to the seller in cash, which expired on August 4, 2014 (see CBOE Research Circular #RS14-366, dated July 8, 2014, for more information).

Contract Adjustment

Pursuant to Article VI, Section 11 and 11A of The Options Clearing Corporation's By-Laws, all outstanding IDIX options as of Wednesday, August 6, 2014, will be adjusted to require, upon exercise, the per-contract delivery or receipt of **\$2,450.00 in cash**. Strike prices will remain the same, and the option symbol will remain **IDIX**. [Any FLEX series that may exist will be adjusted in a similar manner to the standardized option.]

Please be aware that trading in the adjusted IDIX options will be suspended as of Wednesday, August 6, 2014. There are no restrictions on the exercise of the adjusted IDIX options.

Acceleration of Expirations

Pursuant to OCC Rule 807, equity stock option contracts whose deliverables are adjusted to call for cash-only delivery will be subject to an acceleration of the expiration dates for outstanding option series.

All series of Idenix Pharmaceuticals, Inc. options whose expiration dates are after August 16, 2014 will have their expiration dates advanced to Saturday, August 16, 2014. Expiration dates occurring before August 16, 2014 (e.g., Flex options) will remain unchanged.

Questions regarding this memo can be addressed to Options Industry Services at 1-888-OPTIONS (1-888-678-4667). CBOE contract adjustment memos can also be accessed from CBOE.com at the following web address:

<http://www.cboe.com/ContractAdjustments>